ProCE Banner Activity

MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage

MonumenTAL-1 trial showed an objective response rate of 73% to 74% with talquetamab in heavily pretreated patients with R/R MM.

Released: December 16, 2022

Expiration: December 15, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen